Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

TYTao YouHHHaiwen Huang

Discussion

Loading...

Member takes

Overview

Prospective observational study demonstrates improved efficacy and manageable safety of glofitamab in relapsed B-cell lymphomas, highlighting neurotoxicity and infection monitoring.

Key Points

  • To evaluate the efficacy and safety of glofitamab-based salvage therapy in Chinese patients with relapsed or refractory aggressive B-cell lymphomas.
  • Real-world prospective observational study design.
  • Patients aged ≥18 with R/R aggressive B-cell lymphomas received glofitamab plus salvage therapy.
  • Safety and efficacy were assessed via standard monitoring and imaging at regular intervals.
  • Overall response rate in DLBCL patients was 84.1%, with a complete response rate of 43.2%.
  • Median progression-free survival was not reached, with a 1-year PFS rate of 60.75%.
  • Neutropenia was the most common adverse event, affecting 46.9% of patients.

Cite This Study

You et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfcbhttps://doi.org/10.1182/blood-2025-7267
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  2. 2Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  3. 3Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study2025
  4. 4Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  5. 5Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations